Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669617 · ClinicalTrials.gov registry record · Phase 3
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
NCT00669617 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 89 participants.
The verdict
NCT00669617, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg
Interventions
- DRUG Indacaterol
- DRUG Placebo to Indacaterol
- DRUG Salmeterol/fluticasone (50/500 μg)
- DRUG Salbutamol (200 µg)
- DRUG Placebo to Salmeterol/fluticasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669617
The ClinicalTrials.gov registry entry for NCT00669617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Indacaterol is the first listed.
NCT00669617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669617 about?
NCT00669617 is a clinical study titled "Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg
What is the current status of trial NCT00669617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2008-04. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00669617?
The interventions under investigation include: Indacaterol (DRUG), Placebo to Indacaterol (DRUG), Salmeterol/fluticasone (50/500 μg) (DRUG), Salbutamol (200 µg) (DRUG), Placebo to Salmeterol/fluticasone (DRUG).
Who is sponsoring clinical trial NCT00669617?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.